Press "Enter" to skip to content

AstraZeneca-Daiichi Sankyo breast cancer drug shows promise

The treatment Trastuzumab Deruxtecan, or DS-8201, demonstrated a clinically meaningful response in patients with refractory HER2-positive metastatic breast cancer, the two companies said in a joint statement.

Original source:

Also Read:   Amgen takes 20.5% stake in BeiGene to sell cancer drugs in China